The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Psychedelics and the essential importance of context
Abstract
Psychedelic drugs are making waves as modern trials support their therapeutic potential and various media continue to pique public interest. In this opinion piece, we draw attention to a long-recognised component of the psychedelic treatment model, namely ‘set’ and ‘setting’ – subsumed here under the umbrella term ‘context’. We highlight: (a) the pharmacological mechanisms of classic psychedelics (5-HT2A receptor agonism and associated plasticity) that we believe render their effects exceptionally sensitive to context, (b) a study design for testing assumptions regarding positive interactions between psychedelics and context, and (c) new findings from our group regarding contextual determinants of the quality of a psychedelic experience and how acute experience predicts subsequent long-term mental health outcomes. We hope that this article can: (a) inform on good practice in psychedelic research, (b) provide a roadmap for optimising treatment models, and (c) help tackle unhelpful stigma still surrounding these compounds, while developing an evidence base for long-held assumptions about the critical importance of context in relation to psychedelic use that can help minimise harms and maximise potential benefits.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The psychedelic experience comes with an increased sensitivity to internal and external stimuli.”
In the citing paper
“It follows that the general context of psychedelic administration fundamentally shapes drug response and hence safety, as well as potentially therapeutic efficacy [9, 88].”
In the citing paper
“This highlights the frequent clinical observation that patients may need particularly intensive supportive care during, as well as after psychedelic experiences (Carhart-Harris et al., 2018).”
From Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response (2024) · cites this paper as Carhart-Harris et al., 2018
In the citing paper
“Psychedelic experiences vary depending not only on individual characteristics, such as health status, but also on the type of preparation available, intentions agreed upon before the experience, and the environment in which the experience takes place (Carhart-Harris et al., 2018; Golden et al., 2022).”
From Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response (2024) · cites this paper as Carhart-Harris et al., 2018
In the citing paper
“It has long been recognised that both set (the mindset of the participant, including their expectations, assumptions and intentions for the psychedelic experience, as well as stable variables such as personality and the presence of psychopathology) and setting (the physical, social and cultural environment in which the experience occurs) have the potential to greatly impact the outcomes of the Psy”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [43]
In the citing paper
“Contextual factors, such as the environment in which the experience takes place (setting), the mindset of the individual (set), and the support available after the experience (integration and setting), have a huge impact on the effects of psychedelics (85–88).”
From Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (2024) · cites this paper as [85]
In the citing paper
“Differences in set and setting, which involve factors such as opportunity for preparation, guidance and integration by a trained guide, have been extensively shown to greatly influence the acute psychedelic experience (136, 137).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [136]
In the citing paper
“Changes in the ratings of subjective measures that were observed in the present study are not necessarily related to a pharmacological effect of 5-MeO-DMT, but could have resulted from uncontrolled variables such as response expectancy of the participants prior to and after the session or the set and setting of drug administration (Carhart-Harris et al. 2018; Hartogsohn 2016).”
From Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment (2020) · cites this paper as Carhart-Harris et al. 2018
Citations
Cites
Mediators and Mechanisms of Change in Psychotherapy Research
Kazdin, A. E. (2007) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.3.022806.091432 · Cited by 2,504 · cited 1×
“Therapeutic alliance is already known to be a major predictor of response in mental healthcare (Kazdin, 2007) and if the present thesis is correct, its influence is likely to be greater still in the context of psychedelics (see Carhart-Harris and Nutt, 2017).”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 4×
“Indirect support for this may be found in the not inconsiderable (before-versus-after treatment) effects sizes observed in control conditions in recent double-blind randomised control trials of psilocybin for end-of-life distress, for example (Griffiths et al., 2016).”
BackgroundMethodInfluentialRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 2×
“In model 1, it can be seen that: (a) feeling ready to ‘surrender’ to the experience, (b) having a clear intention for it, (c) having the experience in a therapeutic setting, and (d) taking a higher dose, are all predictive of having a certain kind of psychedelic experience which we label ‘peak’ – an intentionally secu…”
BackgroundCaspi, A., Hariri, A. R., Holmes, A., Uher, R., & Moffitt, T. E. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09101452 · Cited by 1,346
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Religions, Values, and Peak-Experiences
Jones, R. G., & Maslow, A. H. (1965) · Journal for the Scientific Study of Religion · doi:10.2307/1384286 · Cited by 949
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Self-citation
Research works printed but not linked: 10
- Aixala M, 2017, Psychotherapeutic Intervention in Integration of Difficult Psychedelic Experiences: The ICEERS Support Service
- Albarelli HP, 2009, A Terrible Mistake: The Murder of Frank Olson and the CIA’s Secret Cold War Experiments
- Hartogsohn I, 2015, The Psycho-Social Construction of LSD: How Set and Setting Shaped the American Psychedelic Experience 1950–1970
- Hartogsohn I, 2017, Drug Sci Pol Law, 3, 1
- Hofmann A, 1980, LSD: My Problem Child
- Krebs TS, 2012, J Psychopharmacol, 26, 994
- Lee MA, 1992, Acid Dreams: The Complete Social History of LSD, the CIA, the Sixties and Beyond
- Schwartz C (2017) Molly at the Marriott: Inside America’s Premier Psychedelics conference. The New York Times. Available at: https://www.nytimes.com/2017/05/06/style/psychedelic-drug-resurgence-daily-life.html (accessed 6 May 2017).
- Sos P, 2013, Neuro Endocrinol Lett, 34, 287
- Waldman A, 2017, A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life
Cited by
Sorted by citations
Items 301–400 of 655
25X-NBOMe compounds – chemistry, pharmacology and toxicology. A comprehensive review
Herian, M., & Świt, P. (2023) · Critical Reviews in Toxicology · doi:10.1080/10408444.2023.2194907 · Cited by 12
Coleman, R. B., Aguirre, K. N., Spiegel, H. P., Pecos, C., Carr, J. A., & Harris, B. N. (2019) · Journal of Comparative Physiology A · doi:10.1007/s00359-019-01351-3 · Cited by 12
Microdosing psychedelics as cognitive and emotional enhancers.
Rifkin, B. D., Maraver, M. J., & Colzato, L. S. (2020) · Psychology of Consciousness Theory Research and Practice · doi:10.1037/cns0000213 · Cited by 15
Kojic, M., Saelens, J., Kadriu, B., Zarate, C. A., & Kraus, C. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_313 · Cited by 12
Classic Psychedelics and Human–Animal Relations
Pöllänen, E., Osika, W., Stenfors, C. U. D., & Simonsson, O. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19138114 · Cited by 11
Zeifman, R. J., Spriggs, M. J., Kettner, H., Lyons, T., Rosas, F. E., Mediano, P. A. M., Erritzøe, D., & Carhart-Harris, R. L. (2022) · doi:10.31234/osf.io/w8j6t · Cited by 12
Self-citationJohansen, L., Liknaitzky, P., Nedeljkovic, M., Mastin-Purcell, L., & Murray, G. (2022) · Systematic Reviews · doi:10.1186/s13643-022-01930-7 · Cited by 11
“It has long been recognised that both set (the mindset of the participant, including their expectations, assumptions and intentions for the psychedelic experience, as well as stable variables such as personality and the presence of psychopathology) and setting (the physical, social and cultural environment in which th…”
BackgroundAltered States of Consciousness During Ceremonial San Pedro Use
Bohn, A., Kiggen, M. H. H., Uthaug, M. V., van Oorsouw, K. I. M., Ramaekers, J. G., & van Schie, H. T. (2022) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2022.2139502 · Cited by 12
Branchi, I. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105272 · Cited by 10
Self-citationBălăeţ, M., Trender, W. R., Hellyer, P. J., & Hampshire, A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1184681 · Cited by 13
Gao, B., Qu, Y.-C., Cai, M., Zhang, Y.-Y., Lu, H., Li, H.-X., Tang, Y., & Shen, H. (2023) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2023.06.006 · Cited by 12
Within-subject comparison of near-death and psychedelic experiences: acute and enduring effects
Martial, C., Carhart-Harris, R. L., & Timmermann, C. (2024) · Neuroscience of Consciousness · doi:10.1093/nc/niae033 · Cited by 13
Self-citationPsychedelic-related deaths in England, Wales and Northern Ireland (1997–2022)
Kopra, E. I., Penttinen, J., Rucker, J., & Copeland, C. S. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111177 · Cited by 12
Negrine, J. J., Puljević, C., Ferris, J., Liknaitzky, P., Perlman, C. M., & Piatkowski, T. M. (2024) · Drug and Alcohol Review · doi:10.1111/dar.13973 · Cited by 11
Beyond psychedelics: set and setting in general psychiatric practice
Kozak, Z., & Miller, C. W. T. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2419662 · Cited by 12
A continuum hypothesis of psychotomimetic rapid antidepressants
Haarsma, J., Harmer, C. J., & Tamm, S. (2021) · Brain and Neuroscience Advances · doi:10.1177/23982128211007772 · Cited by 13
On Revelations and Revolutions: Drinking Ayahuasca Among Palestinians Under Israeli Occupation
Roseman, L., & Karkabi, N. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.718934 · Cited by 11
Self-citationShaw, L., Rea, K., Lachowsky, N. J., & Roth, E. A. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2054746 · Cited by 11
The Relationship Between Naturalistic Psychedelic Use and Clinical Care in Canada
Glynos, N. G., Kruger, D. J., Kolbman, N., Boehnke, K. F., & Lucas, P. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2242353 · Cited by 13
Challenges in translational research: MDMA in the laboratory versus therapeutic settings
de Wit, H., Bershad, A. K., & Grob, C. S. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211015221 · Cited by 11
Focusing on the negative: cases of long-term negative psychological responses to psychedelicsPreprint
Bremler, R., Katati, N., Shergill, P., Erritzøe, D., & Carhart-Harris, R. L. (2023) · doi:10.31234/osf.io/yzmcj · Cited by 11
Self-citationSelf-Care Practices with Psychedelics–A Qualitative Study of Users’ Perspectives
Soares, C. M., Leite, Â., & Pinto, M. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2071134 · Cited by 10
Current perspectives on psychedelic treatments in Europe
Madero, S., Soto-Angona, Ó., Oña, G., Sánchez‐Moreno, J., & Vieta, E. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101537 · Cited by 10
Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests
Jones, G. M., Al‐Suwaidi, M., Castro‐Ramirez, F., McGuire, T. C., Mair, P., & Nock, M. K. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1169692 · Cited by 10
Glynos, N. G., Baker, A., Aday, J. S., Pouyan, N., Barron, J., Herberholz, M., Kruger, D. J., & Boehnke, K. F. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2405685 · Cited by 10
Yaden, D. B., Graziosi, M., Owen, A. M., Agin-Liebes, G., Aaronson, S. T., Allen, K. E., Barrett, F. S., Bogenschutz, M. P., Carhart-Harris, R. L., Ching, T. H. W., et al. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0019 · Cited by 12
Self-citationThe ketamine chameleon: history, pharmacology, and the contested value of experience
Diep, D., de la Salle, S., Lévesque, J. T., Lifshitz, M., Garel, N., & Greenway, K. T. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2459377 · Cited by 10
Ragnhildstveit, A., Kaiyo, M., Snyder, M. B., Jackson, L. K., Lopez, A., Mayo, C., Miranda, A. C., August, R. J., Seli, P., Robison, R. J., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1051542 · Cited by 10
Effect of LSD and music on the time-varying brain dynamics
Adamska-Stolarczyk, I., & Finc, K. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06394-8 · Cited by 12
Minorities’ diminished psychedelic returns: Cardio-metabolic health
Viña, S. M. (2024) · Drug Science Policy and Law · doi:10.1177/20503245231225756 · Cited by 10
Hirschfeld, T., Smit‐Rigter, L. A., van der Gouwe, D., Reiche, S., Stöver, H., & Majić, T. (2021) · Current Addiction Reports · doi:10.1007/s40429-021-00385-5 · Cited by 10
Context is a Critical for Psychoactive Drug Effects
Greenway, K. T. (2023) · CNS Drugs · doi:10.1007/s40263-023-01053-0 · Cited by 9
Perceived attachment history predicts psychedelic experiences: A naturalistic study
Cherniak, A. D., Mikulincer, M., Brulin, J. G., & Granqvist, P. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00330 · Cited by 10
Butler, M., Bird, C., Maggio, C., Durden, A., Modlin, N. L., Campbell‐Coker, K., Edwards, M. J., Pick, S., Millman, L. S. M., Lowery, E., et al. (2024) · Wellcome Open Research · doi:10.12688/wellcomeopenres.22543.1 · Cited by 9
Chen, M., Cheng, S.-L., Kao, Y., Tseng, P., Hsu, C., Yu, C., Yang, F., Thompson, T., Hsu, T., & Liang, C. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1439347 · Cited by 9
Considering distinct positive emotions in psychedelic science
Goldy, S. P., Hendricks, P. S., Keltner, D. J., & Yaden, D. B. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2394221 · Cited by 9
Stroud, J., Rice, C., Orsini, A., Schlosser, M., Lee, J., Mandy, W., & Kamboj, S. K. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06685-8 · Cited by 11
Modlin, N. L., McPhee, T., Zazon, N., Sarang, M., Hignett, R., Pick, S., Cleare, A. J., Williamson, V., & Rucker, J. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2024.0027 · Cited by 10
Healy, C. J., Frazier, A., Kirsch, S., Sanford, A., Garcia‐Romeu, A., Todman, M., Varon, J. P., & D'Andrea, W. M. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111361 · Cited by 9
Wießner, I., Falchi-Carvalho, M., Laborde, S., Barros, H., Bolcont, R., Silva, S. R. B., Pantrigo, É. J., Medina, M., Arichelle, F., de Almeida, R. N., et al. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.06.002 · Cited by 9
A Scoping Review of Research in Naturalistic Studies with Psychedelics
de Carvalho, L. L., Encantado, J., Kettner, H., Timmermann, C., Veiga, D., & Teixeira, P. J. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2520221 · Cited by 10
Naturalistic psychedelic use and changes in depressive symptoms
Simonsson, O., Hendricks, P. S., Swords, C. M., Osika, W., & Goldberg, S. B. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119857 · Cited by 9
Synaptic priming: A framework for pharmacotherapy in depression
Brown, K. A., Ajibola, M. I., Medeiros, G. C., & Gould, T. D. (2025) · Neuron · doi:10.1016/j.neuron.2025.09.010 · Cited by 11
Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice
Gobbi, G., Inserra, A., Greenway, K. T., Lifshitz, M., & Kirmayer, L. J. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221119388 · Cited by 10
IsHak, W. W., García, P., Pearl, R., Dang, J., William, C., Totlani, J., & Danovitch, I. (2023) · PubMed Central · Cited by 8
Thal, S. B., Daniels, J. K., & Jungaberle, H. (2019) · Journal of Substance Use · doi:10.1080/14659891.2019.1614234 · Cited by 9
Godfrey, K. E. M., Weiss, B., Zhang, X., Spriggs, M. J., Peill, J. M., Lyons, T., Carhart-Harris, R. L., & Erritzøe, D. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104092 · Cited by 10
Self-citationPsychedelics and psychological strengths
Brasher, T. J., Rosen, D., & Spinella, M. (2023) · International Journal of Wellbeing · doi:10.5502/ijw.v13i1.2325 · Cited by 10
Žuljević, M. F., Mijatović, A., Marušić, S. L., Kudrjavets, G., Buljan, I., & Hren, D. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2274382 · Cited by 8
Mian, M. N., Altman, B. R., Low, F., & Earleywine, M. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231214060 · Cited by 10
EMBARK Psychedelic Therapy for Depression
Brennan, B., & Belser, A. (2024) · doi:10.1093/9780197762622.001.0001 · Cited by 8
Psychology of Religion Approaches to the Study of Religious Experience
Taves, A. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108575119.004 · Cited by 10
Positive Affect and Letheby's Naturalization of Psychedelic Therapy
Hoffman, S. (2022) · Philosophy and the Mind Sciences · doi:10.33735/phimisci.2022.9285 · Cited by 7
The neuroscience of breathlessness
Pick, A., Gnanarajah, S., Fraser, E., & Pattinson, K. T. S. (2022) · European Respiratory Society eBooks · doi:10.1183/2312508x.10012621 · Cited by 8
Exline, J. J., Schutt, W. A., Pait, K. C., & Wilt, J. A. (2022) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2022.2148062 · Cited by 8
Savoldi, R., Roazzi, A., & Sales, R. C. D. O. (2023) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2023.2185369 · Cited by 8
Arnaud, K. O. S., & Sharpe, D. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00263 · Cited by 10
How Level is the 'Cognitive Playing Field'?
Martin, J. M., & Sterzer, P. (2022) · Philosophy and the Mind Sciences · doi:10.33735/phimisci.2022.9326 · Cited by 7
Zhou, K., Wied, D. D., Carhart-Harris, R. L., & Kettner, H. (2022) · doi:10.31234/osf.io/txzha · Cited by 8
Self-citationVohryzek, J., Luppi, A. I., Atasoy, S., Deco, G., Timmermann, C., Carhart-Harris, R. L., & Kringelbach, M. L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.30.596410 · Cited by 8
Self-citationDelli Colli, C., Viglione, A., Poggini, S., Cirulli, F., Chiarotti, F., Giuliani, A., & Branchi, I. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03246-1 · Cited by 7
Self-citationArmand, S., Larsen, K., Madsen, M. K., Ozenne, B., Preller, K. H., Knudsen, G. M., Stenbæk, D. S., & Fisher, P. M. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.103934 · Cited by 7
Black, J. C., Monte, A. A., Dasgupta, N., Jewell, J. S., Rockhill, K. M., Olson, R. A., & Dart, R. C. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00233-1 · Cited by 7
Navigating the mainstreaming of psychedelics
Labate, B. C., Antunes, H. F., Beachy, J., Sloshower, J., & Cavnar, C. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00429 · Cited by 7
Glynos, N. G., Baker, A., Aday, J. S., Kruger, D. J., Boehnke, K. F., Lake, S., & Lucas, P. (2025) · British Journal of Pain · doi:10.1177/20494637251319497 · Cited by 7
Transient destabilization of whole brain dynamics induced by N,N-Dimethyltryptamine (DMT)
Piccinini, J., Perl, Y. S., Pallavicini, C., Deco, G., Kringelbach, M. L., Nutt, D., Carhart-Harris, R. L., Timmermann, C., & Tagliazucchi, E. (2025) · Communications Biology · doi:10.1038/s42003-025-07576-0 · Cited by 8
Self-citationAesthetic quality of psychedelic experience is linked to insight and psychological outcomes
Hooper, J., Gyongyosi, E., Hutchison, K. E., & Mueller, R. L. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1533055 · Cited by 7
Roseby, W., Kettner, H., Roseman, L., Spriggs, M. J., Lyons, T., Peill, J., Giribaldi, B., Erritzøe, D., Nutt, D. J., & Carhart-Harris, R. L. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1580663 · Cited by 8
Self-citationThe Failed Globalization of Psychedelic Drugs in the Early Modern World
Breen, B. (2021) · The Historical Journal · doi:10.1017/s0018246x21000224 · Cited by 7
Development of the Japanese version of the 30‐item Mystical Experience Questionnaire
Yonezawa, K., Tani, H., Nakajima, S., & Uchida, H. (2023) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12377 · Cited by 6
Altman, B. M., & Magnus, M. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241278774 · Cited by 7
Wahba, M., Hayes, C., Kletter, M., & McAllister-Williams, H. (2024) · BJPsych Open · doi:10.1192/bjo.2024.768 · Cited by 7
Educational moderation of gender disparities in psychedelic health outcomes
Viña, S. M. (2025) · Academia Mental Health and Well-Being · doi:10.20935/mhealthwellb7580 · Cited by 7
Bender, D. A., Nayak, S. M., Siegel, J. S., Hellerstein, D. J., Erçal, B., & Lenze, E. J. (2025) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.20240025 · Cited by 7
Cyberdelics: Context engineering psychedelics for altered traits
Smith, C. H., & Warner, M. (2022) · Electronic workshops in computing · doi:10.14236/ewic/eva2022.48 · Cited by 7
LIMITATIONS ON THE SCIENTIFIC STUDY OF DRUG‐ENABLED MYSTICAL EXPERIENCES
Jones, R. H. (2019) · Zygon® · doi:10.1111/zygo.12546 · Cited by 7
The Promise and Demise of LSD Psychotherapy in Norway
Haave, P., & Pedersen, W. (2019) · Social History of Medicine · doi:10.1093/shm/hkz128 · Cited by 7
Cavanna, F., Muller, S. L., de la Fuente, L. A., Zamberlán, F., Palmucci, M., Janeckova, L., Kuchař, M., Pallavicini, C., & Tagliazucchi, E. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.30.470657 · Cited by 7
Albert, A. E., & Back, A. L. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1529427 · Cited by 6
Irrmischer, M., Puxty, D. J., Yıldırım, B. O., Deijen, J. B., & Engelbregt, H. (2025) · Psychopharmacology · doi:10.1007/s00213-024-06733-3 · Cited by 7
Dwyer, J., Johnston, R. B., O'Callaghan, C., Kallianis, V., & Ross, M. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1541528 · Cited by 6
Forsberg, S., Downey, A. E., Bruett, L. D., Hail, L., Fernandes‐Osterhold, G., Woolley, J. D., Lafrance, A., & Raymond‐Flesch, M. (2025) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/s13034-025-00930-4 · Cited by 6
Experiments in medicalization: psychedelic therapy in Switzerland and Australia
Langlitz, N. (2025) · BioSocieties · doi:10.1057/s41292-025-00369-y · Cited by 6
Is music a drug? How music listening may trigger neurochemical responses in the brain
Reybrouck, M., & Dyck, E. V. (2024) · Musicae Scientiae · doi:10.1177/10298649241236770 · Cited by 17
Hardy, J., Kettner, H., Wall, J., Wall, J., Carhart-Harris, R. L., & Hardy, J. L. (2025) · Frontiers in Virtual Reality · doi:10.3389/frvir.2024.1466362 · Cited by 7
Self-citationJiwani, Z., Goldberg, S. B., Stroud, J., Young, J., Curtin, J., Dunne, J. D., Simonsson, O., Webb, C. A., Carhart-Harris, R., & Schlosser, M. (2025) · PLOS ONE · doi:10.1371/journal.pone.0310160 · Cited by 6
Self-citationFalcon, J. (2025) · Anthropology of Consciousness · doi:10.1111/anoc.70002 · Cited by 6
New Insights Into the Clinical and Nonclinical Effects of Psychedelic Substances
Forstmann, M., & Sagioglou, C. (2021) · European Psychologist · doi:10.1027/1016-9040/a000447 · Cited by 7
User perceptions of long-term costs and benefits of MDMA use: findings from a large online sample
Elsey, J. W. B., Wuestman, V. A. F., & Fieten, A. (2023) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2023.2284643 · Cited by 6
An Occupational Perspective on Psychedelic Therapy: A Scoping Review
Hogan, G. A., Wagner, K. E., Tichenor, E., & Barlott, T. (2024) · Canadian Journal of Occupational Therapy · doi:10.1177/00084174241228678 · Cited by 7
Chiamulera, C., Benvegnù, G., Piva, A., & Paolone, G. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105648 · Cited by 6
Leveraging meditation research for the study of psychedelic-related adverse effects
Palitsky, R., Canby, N. K., Dam, N. T. V., Levin-Aspenson, H. F., Kaplan, D. M., Maples‐Keller, J. L., Raison, C. L., Grant, G. H., Dunlop, B. W., & Britton, W. B. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2420745 · Cited by 7
Luoma, J. B., Davis, A. K., Watts, R., & McCracken, L. M. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2020.01.004 · Cited by 6
Self-citationAdvancing elite athlete mental health treatment with psychedelic-assisted psychotherapy
Walton, C. C., & Liknaitzky, P. (2020) · Journal of Applied Sport Psychology · doi:10.1080/10413200.2020.1848941 · Cited by 6
The Psychedelic Social Club: a regulatory concept for people who use psychedelics?
Harder, H., Steinmetz, F. P., & Kohek, M. (2023) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2023.2276067 · Cited by 6
Mapping a cognitive theory onto neurologyPreprint
Friesen, L. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/9mbuv · Cited by 6
Ayyagari, M. M., Heim, D., Sumnall, H. R., & Monk, R. L. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105822 · Cited by 5
Geller, J. A., & Whitney, E. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01577-2 · Cited by 5
Perivoliotis, D., Knopp, K. C., Remick, S., Kaigle, A., Stauffer, C. S., Khalifian, C. E., Wachsman, T. R., Chargin, B. E., Bismark, A. W., Alam, A., et al. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1433999 · Cited by 6
Pasquini, L., Simon, A. J., Gallen, C. L., Kettner, H., Roseman, L., Gazzaley, A. H., Carhart-Harris, R. L., & Timmermann, C. (2025) · Imaging Neuroscience · doi:10.1162/imag_a_00541 · Cited by 5
Self-citation
Metadata
- Authors
- Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M.
- Affiliations
- Imperial College London (GB)
- Psychedelic Research Group, Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK
- Istituto Superiore di Sanità (IT)
- Corresponding author
- Carhart-Harris, Robin L
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2018-02-15
- Volume
- 32
- Issue
- 7
- Pages
- 725-731
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2788854095
- Cited by
- 657
- References
- 62
- Citations by year
- 2026: 83 · 2025: 102 · 2024: 112 · 2023: 105 · 2022: 97 · 2021: 72 · 2020: 49 · 2019: 24 · 2018: 13
- FWCI
- 46.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute for Health and Care Research (ACF-2013-21-501)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psychedelics, set and setting, context effects, 5-HT2A receptor agonism, neuroplasticity, long-term mental health outcomes, harm reduction
- MeSH terms
- Animals, Clinical Trials as Topic, Hallucinogens, Humans, Research Design, Serotonin 5-HT2 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
